

September 22, 2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Subject: Investor Presentation

Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to our intimation dated September 19, 2025, enclosed is the Investor Presentation for the Pharma and Healthcare conference – by DAM Capital Advisors Limited, to be held on September 23, 2025.

This is for your information and for public at large.

Thanking you,

Yours faithfully,

For Advanced Enzyme Technologies Limited

Sanjay Basantani

Company Secretary and Head – Legal

Encl.: As above



Advanced Enzyme Technologies Limited

Investors Presentation | September 2025



Safe Harbour Statement

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

Table of Content

Company Overview	04
Global Markets	12
Unique Investment Case	18
Future Growth Strategies & Pipeline	27
Annexures	30
Shareholders' Information	35



Company Overview



Company Overview

Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.



What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

We use enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.

What are Probiotics?

Probiotics are live microorganisms, when administered in sufficient amount, confer health benefits to human and animals. Probiotics have now become an integral part of several therapies for the digestive disorders and newer applications for treatment of several other diseases are being developed. Probiotics act by fighting with the disease causing microorganisms and by secreting beneficial metabolites in the human/animal system.

Advanced Enzymes has developed and upscaled technologies for the production and application of several important probiotics.



Mission

It is our mission to see that every human being is able to take advantage of the power of enzymes and probiotics for well-being and leading a healthy life!



Vision

Our vision at Advanced Enzymes is to become the largest, enzyme and probiotic -based, value provider to consumers and processors globally!

Board of Directors



Mr. Vasant Rath

Promoter Chairman and Non-Executive Director



Mr. Mukund M. Kabra

Whole-time Director



Mr. Pramod Kasat

Independent Director



Ms. Rasika Rath

Non-Executive Director



Mr. Vinod Jajoo

Independent Director



Mr. Sunny Sharma

Non-Executive Director



Ms. Rajshree Patel

Independent Director



Mr. Nitin Deshmukh

Independent Director



Ms. Vandana Tilak

Independent Director


Management Team



Mr. Beni Prasad Rauka
Chief Financial Officer



Mr. Dipak Roda
Sr. Vice President / Market & Business Development



Mr. Harshad Doshi
CFO & COO - Advanced Enzymes, USA



Ms. Martina Doering
Managing Director /Head Of Business Development - evoxx Technologies, Germany



Ms. Rasika Rathi
General Counsel / Vice President And Secretary - Advanced Enzymes, USA



Dr. Michael Puls
Managing Director /Head Of Research and Development - evoxx Technologies, Germany



Mr. Sanjay Basantani
Company Secretary & Head Legal

Advanced Enzyme Technologies Limited – A Rising Global Star



Note: Facts & Figures as on March, 2025
* Patents includes the filed applications
#Food Dossier filed with EFSA, out of which positive opinion is received for 9 Dossiers & 6 are under evaluation
**No question letter received for 7 Dossier, 1 is self-affirmed and another 1 is under evaluation
##Novel food dossier has been filed with EFSA is under evaluation
All the numbers are as per IndAs

Presence Across Globe

International Presence

9

Manufacturing Facilities

INDIA

Maharashtra	6
Madhya Pradesh	1
Andhra Pradesh	1

USA

California	1
------------	---

7

R&D Locations

INDIA

Maharashtra	4
Andhra Pradesh	1

GERMANY

North Rhine-Westfalia	1
-----------------------	---

USA

California	1
------------	---

The figure consists of a world map and a donut chart. The world map shows the global presence of the company, with dark blue areas indicating international presence and green location pins indicating manufacturing facilities. The donut chart shows the distribution of manufacturing facilities by region for FY25.


Region	Percentage
India	46%
USA	37%
Europe	9%
Asia	5%
Rest of the World	3%

Investors Presentation | September'25


9

advanced enzymes
Where ENZYME is Life

Catering to Diverse end-use Industries




Brief History and Evolution




Note: Text marked in green indicates acquisition

Global Enzymes Market

How Big is the Global Opportunity?



Competitive Scenario in the Global Enzymes and Probiotics Markets	
Pharmaceutical	Anthem Biosciences
Nutraceutical	Novonesis, DSM, Archer Daniel Midland
Probiotics	Danone, Yakult, Novonesis, Sabinsa, Kerry, Lallemand, Unique Biotech
Bio-Catalysis	Codexis, Cambrex, Sigma-Aldrich, Lonza, Biosyntia, BASF SE, Amano Enzymes and other regional players
Animal Nutrition	Novonesis, DSM, Kemin, Novus, Alltech, Cargill, BASF SE, Biomin
Bio-Processing	Food: AB Enzymes, DSM, Novonesis, Kerry Foods
	Non-Food: Novonesis, DuPont, DSM, AB Enzymes, Amano Enzymes



Source: Market and Markets | Precedence Research | The Business Research | Meticulous Research

What we are Aiming in the Opportunity?

Focus Area	Opportunity Size for AETL	Addressable market for AETL over next 5 years**	CARG(%) over next 5 years	AETL’s Current Share of Revenue	
				FY25	FY24
Human Nutrition					
Pharma/API	\$ 80 mn	\$ 50 mn	6%	\$ 18.04 mn, 24%	\$ 20.32 mn, 27%
Probiotics	\$13 bn	\$250 mn	14%	\$ 4.3 mn, 6%	\$ 3.7 mn, 5%
Bio-catalysis	\$316 mn	\$60 mn	6%	\$ 2.1 mn, 3%	\$ 3.3 mn, 4%
Nutrition	\$200 mn	\$200 mn	8%	\$23.45 mn, 31%	\$23.23 mn, 31%
Animal Nutrition					
	\$ 2 bn	\$800 mn	8%	\$ 9.0 mn, 12%	\$ 8.2 mn, 11%
Bio-Processing					
Food	\$1.1 bn	\$385 mn	7%	\$9.57 mn, 13%	\$9.37 mn, 12%
Non-Food	\$400 mn	\$100 mn	7%	\$2.5 mn, 3%	\$2.25 mn, 3%
Specialized Manufacturing					
	-	\$100 mn	8%	\$6.4 mn, 8%	\$5 mn, 7%

**Opportunity size and the addressable market are as per Company's own estimates

*As of now we are considering the India only opportunity for Bio-catalysis

Products and Competitive Landscape

Business Division	Usage	Product	Competitors	Geography
Pharma/API	Anti-inflammatory, Digestive Enzymes including lactose intolerant	Serratiopeptidase, Fungal diastase, Fungal lactase, amylase, lipase, protease, maltase, trypsin, pepsin	Anthem Biosciences	India
Probiotics	Human (Pre-biotic, Probiotic), Animal	Clausii, Subtilis Coagulans, Saccharomyces Boulardii, Rhamnosus, Lactic Acid Bacillus, Sporogenus	Danone, Yakult, Novonesis, Sabinsa, Kerry, Lallemand, Unique Biotech, Senzyme, Evonik, DSM, Lesaffre, Alltech	India, Americas
Bio-catalase	Pharma, Food Industry, Non-Food Industry	Alcohol Dehydrogenase, Halohydrin Dehalogenase, Transaminase, Lipase	Concord Biotech, Laurus Labs, Codexis, Cambrex, Sigma-Aldrich, Lonza, Biosyntia, BASF SE, Amano Enzymes	India
Nutrition (international Sales)	Anti-inflammatory, Antii-allergent, Digestive health, Sports supplements, Oral health, joint health	Serratiopeptidase, Nattokinase, Fungal diastase, Fungal lactase, amylase, sucrose, lipase, protease, maltase, trypsin, pepsin	Novonesis, BASF SE, Merck KGaA (Millipore Sigma), IFF, Amano Enzyme, Creative Enzymes, Biocatalysts Ltd., Alfanzyme Group	Americas, Other geographies
Animal Nutrition	Animal Feed(incl. Digestive Enzymes, Mycotoxin Binders), Pet Health (Digestive, Oral, Skin, Joint)	Protease, Phytase, Xylanase, Mannanase, Cellulase, Betaglucanase, Alpha Gallactosidase etc. and with probiotics combination	Novonesis, DSM, Kemin, Novus, Alltech, Cargill, BASF SE, Biomin and other regional players	India, Asia, Americas
Bio-Processing - Food	Baking, Brewing & Malting, Oil & Fat extraction, Beverages	Amylase, Glucanase, Gluca oxidase, Lipase, Xylanase etc.	Novonesis, DuPont / Danisco (IFF), DSM-Firmenich, AB Enzymes, Amano Enzyme, BASF SE, Kerry Group plc	India, Europe, USA, Africa, Asia
Bio-Processing - Non-Food	Textile, Leather, Paper	Amylase, Cellulase, Alkaline xylanase, Protease, Mannanase, Catalase, Lipase	BASF SE, DuPont, AB Enzymes, DSM, Amano Enzyme, Dyadic International, IFF, Aumgene Biosciences, Fineotex Chemical Ltd, Tex Biosciences	India, Europe, Africa, Asia
Specialized Manufacturing	Pharmaceuticals, Nutraceuticals, Dietary, Food supplements, Cosmetics, Poultry, Petcare	Effervescent (Sachets & Tablets), Vaccines	Life Vision Healthcare, Groweal Nutraceutical, Medlab Pharmaceuticals, Dev Lifesciences, and Fullife Healthcare	India, Europe, USA, Africa, Asia

Demand drivers for Enzyme Market (1/2)



Human Healthcare Enzymes

- Aging Global Population
- Rising Prevalence of Chronic Diseases
- Growing Focus on Preventive and Personalized Healthcare
- Increasing Consumer Awareness and Health Consciousness
- Growth of the Nutraceuticals and Functional Foods Market
- Expanding Middle-Class Population and Urbanization
- Regulatory Push for Quality and Transparency
- Corporate Wellness and Workplace Health Initiatives



Animal Healthcare Enzymes

- Rising Demand for Animal Protein
- Efficiency in Feed Utilization
- Ban on Antibiotic Growth Promoters (AGPs)
- Increasing Focus on Animal Health and Welfare
- Environmental Concerns and Sustainability
- Growth of the Compound Feed Industry
- Rise of Commercial Poultry and Aquaculture



Biocatalysis

- Shift Toward Green and Sustainable Chemistry
- Rising Demand in the Pharmaceutical, Fine and Specialty Chemicals
- Advances in Enzyme Engineering and Synthetic Biology
- Growing Bioplastics and Biofuels Industry
- Industrial Adoption and Process Integration
- Consumer Demand for Natural and Clean-Label Products



Food Enzymes

- Increasing Demand for Processed and Packaged Foods
- Clean Label and Natural Product Trends
- Growing Demand for Functional and Health-Oriented Foods
- Expansion of the Bakery, Dairy, and Beverage Segments
- Increasing Need for Production Efficiency and Cost Reduction
- Focus on Waste Reduction and Sustainability
- Regulatory Support and GRAS (Generally Recognized as Safe) Status



Probiotics

- Rising Health Awareness and Preventive Healthcare Trends
- Increasing Incidence of Digestive Disorders
- Growing Demand for Functional Foods and Beverages
- Personalized Nutrition and Microbiome Innovation
- Rapid Growth in E-Commerce and Direct-to-Consumer Channels
- Expanding Pet and Animal Nutrition Market
- Growth in Emerging Markets



Non-Food Enzymes

- Rising Demand for Green and Sustainable Industrial Processes
- Growth in the Biofuels Sector
- Expanding Textile and Leather Processing Industry
- Rising Adoption in Detergent and Cleaning Products
- Innovation in Pharmaceutical Manufacturing
- Pulp and Paper Industry Optimization
- Waste Management and Environmental Biotechnology
- Regulatory and Consumer Pressure for Eco-Friendly Products

Demand drivers for Nutraceutical Market



Increasing prevalence of chronic & non-communicable diseases

Poor nutrition due to globalisation and urbanisation in developing countries



Escalating healthcare expenses

Consumers are seeking nutraceuticals for health benefits as alternatives to prescription drugs and over-the-counter medications



Increasing desire for convenience

Growing need among consumers for convenient nutraceutical options like gummies, effervescent tablets, snack bars, etc.



Lack of faith on traditional medicine

The rising concern over the side effects of pharmaceutical drugs, including Covid-19 vaccines and treatments



Baby Boomer's desire to relish retirement

Baby Boomer's, with greater disposable income with a desire to maintain a healthy lifestyle throughout retirement



Growing popularity of dietary supplement

Increasing popularity of supplements as a form of preventive care, fuelled by those struggling with lifestyle illnesses and aging issues



Surging interest in fitness nutrition

Sports nutrition products are promoting wellness for non-athletes are becoming popular among regular exercisers and hobbyists


Advanced Enzymes - A Unique Investment Case




What Makes AETL a Unique Investment Case?



Integrated Player with Presence Across the Enzyme Value Chain



Strong Research & Development Capabilities



68+ Enzymes & Probiotics	15 [#] Food Enzymes Dossiers filed with EFSA ⁽¹⁾	17* Registered Patents
100+ Scientists, Microbiologists, Engineers, Food Technologists, Biotechnologists	9** GRAS Dossier filed with US FDA	1 ^{##} Novel Food Dossier filed with EFSA

Enzyme Engineering	Microbial Engineering & Strain Development	Process Development & Scale-Up	Application Development & Customer Solution
<ul style="list-style-type: none">Designing the right set of enzymes with their target applications in mindInvolves techniques such as Directed Evolution, Rational Design, Quantum Mechanics, etc.	<ul style="list-style-type: none">Developing new & improved microbial systems for enzyme productionDeveloping strains with better characteristics such as rapid growth, higher productivity, cheaper media cost, etc.	<ul style="list-style-type: none">Developing robust & scalable processes, both in fermentation as well as downstream processingEnhancing recovery & yields, to ensure sufficient productivity & commercial feasibility	<ul style="list-style-type: none">Understanding problems related to customers' products & processes, and designing the most effective solutionsConducting lab & plant trials to deliver the end results





1) EFSA = European Food Safety Authority | (2) On a Consolidated basis (in ₹ mn) | (3) As of March 31st, 2025
*Patents includes the filed applications
#Food Dossier filed with EFSA, out of which positive opinion is received for 9 Dossiers & 6 are under evaluation
**No question letter received for 7 Dossier, another 1 are under evaluation
Novel Food Dossier has been filed with EFSA is under evaluation

Specialized Business With High Entry Barriers



Strong Financial Performance – FY25

(₹ in Million)




Note:


1. All the numbers are as per IndAs
2. All numbers are on Consolidated basis
3. All the decimals are rounded off to their relevant nearest number

Strong Financial Performance – FY25


Net Working Capital (Days)




Net Worth (₹ mn)



ROE (%) & ROCE (%)



Net Debt to Equity (x)



Note: All the numbers are as per IndAs


All numbers are on Consolidated basis

Net working capital days = ((Trade receivables + inventories - Trade payables) / Revenue from operations) * 365

Net Debt = Long term debt + short term debt + current maturities of long term debt - Cash & Cash Equivalent

ROE = Profit after tax / Average shareholder equity; ROCE = (Net Profit before Tax, Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth)

Results Summary – Q1 FY26 (Consolidated)



***Notes:**

1. On Consolidated Basis
2. PAT is before minority
3. Ind AS adjustments are carried out on account of commission, discount, and provision for sales return
4. All the decimals are rounded off to their relevant nearest number

Balance Sheet (Consolidated) – FY25

(₹ in Million)

Particulars	FY25 Audited	FY24 Audited	FY23 Audited	FY22 Audited	FY21 Audited
Assets					
Property, plant and equipment	2,929	2,765	2,732	2,622	2,462
Capital work-in-progress	217	411	215	151	102
Intangible assets	523	479	550	609	693
Goodwill	3,334	3,253	3,209	2,961	2,887
Other non-current assets	411	350	291	289	258
Current assets	8,799	8,098	7,221	6,044	5,160
Total Assets	16,123	15,356	14,218	12,676	11,562
Equity And Liabilities					
Equity share capital	224	224	224	224	223
Other equity	13,985	13,018	12,127	10,662	9,486
Non-controlling interest	478	470	491	518	617
Non-current liabilities	559	580	601	668	560
Current liabilities	967	1,064	775	604	676
Total – Equity and Liabilities	16,213	15,356	14,218	12,676	11,562


Notes:

1. All the decimals are rounded off to their relevant nearest number

Future Growth Strategies & Pipeline




Key Strategies for Future Growth



Focus Areas Going Ahead

Animal Nutrition



Continuing conduct trials and studies to bring newer and effective nutritional products, which may improve the efficacy of animal feeds

Registering and introducing more products in the domestic as well as in the international markets.

Expand its sales and marketing team in USA, MENA and Asian market

Targeting to strengthen the geographical reach and distribution network by appointing more distributors in the overseas markets

Probiotics



To introduce more probiotics products in Human Nutrition for the immunity development, active health food, gut health and various nutraceutical applications

To launch more products on immunity development, digestion improvement, and increase nutritional level of feed in the Animal Nutrition

Bio-Catalysis



Developing bio catalysis for API manufacturers, providing enzymatic based solutions that are target specific, helping them to save cost of energy, time and use of chemicals

Couple of products are under the advanced stage of trials at plant level by the API manufacturers

This is one of the opportunities, where your Company will continue its efforts and focus

Baking



In Bio-processing division, our focus is on Baking Solutions

We have got positive response for the products in terms of efficacy and performance

Confident to expand in Europe, Americas and Rest of World to tap the available opportunities by offering a value based approach in the Baking Industry


Annexures



Segment-wise Performance




Human Nutrition




Bio-Processing


(₹ in Million)



Animal Nutrition




Specialized Manufacturing




Geography-wise Performance




India




Americas




Europe



Asia (Ex-India)



Rest of the World



Profit & Loss (Consolidated) – Q1 FY26 & FY25

(₹ in Million)

Particulars	Q1 FY26 Un-Audited	Q4 FY25 Audited	Q1 FY25 Un-Audited	Y-o-Y (%)	Q-o-Q (%)	FY25 Audited	FY24 Audited	Y-o-Y (%)
Income from Operations	1,859	1,672	1,545	20%	11%	6,369	6,239	2%
Expenses	1,391	1,317	1,120	24%	6%	4,790	4,547	5%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	468	355	425	10%	32%	1,579	1,692	-7%
Other Income	88	87	70	27%	1%	330	367	-10%
Profit from ordinary activities before Finance Costs and Exceptional Item	557	443	495	12%	26%	1,909	2,059	-7%
Finance costs	8	8	9	-13%	-6%	36	29	23%
Profit from ordinary activities before Exceptional items and Tax	549	435	487	13%	26%	1,874	2,030	-8%
Exceptional item	-	-	-	-	-	-	151	-
Profit from ordinary activities before Tax	549	435	487	13%	26%	1,874	1,879	0%
Tax	145	167	137	6%	-14%	534	509	5%
Net Profit for the period	404	267	350	16%	51%	1,340	1,370	-2%
Earnings Per Share	3.57	2.37	3.05	17%	51%	11.72	11.92	-2%

*Notes:

1. On Consolidated Basis
2. PAT is before minority
3. Ind AS adjustments are carried out on account of commission, discount, and provision for sales return
4. All the decimals are rounded off to their relevant nearest number




Corporate Structure



Note: Advanced Enzymes currently holds 95.72% in JC Biotech
Dynamic Enzymes has been merged with AST Enzymes on 24th Feb 2023

Shareholders' Information

Stock Data

	Market Capitalization (₹)	35,970 mn
	Shares Outstanding	111.88 mn
	Symbol (NSE/ BSE)	ADVENZYMES / 540025


Stock Chart



Top Institutional Holders

Institutions	OS (%)
ORBIMED ASIA III MAURITIUS	12.07
NALANDA INDIA EQUITY FUND	8.46
ICICI PRUDENTIAL MF	3.08
CLARUS CAPITAL I	2.27
MARVAL CAPITAL	1.00
UTI MF	0.93

Shareholding Pattern (%)



Source: NSE
Note: Data mentioned on this slide is as on 30th June 2025

Thank You

Advanced Enzyme Technologies Limited

Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road,
Louiswadi, Thane (W) 400 604, India

Tel: +91-22-4170 3200

Fax: + 91-22-25835159

Web: www.advancedenzymes.com

CIN No: L24200MH1989PLC051018

Investor Relations Contact:

Ronak Saraf

Manager - Investor Relations

✉ ir@advancedenzymes.com

☎ +91 86578 64146

